PREDICTIVE VALUE OF QUANTITATIVE <sup>18</sup> F‐FDG‐PET‐CT RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA
نویسندگان
چکیده
Introduction: About 20% of patients with classical Hodgkin lymphoma (cHL) relapse or are primary refractory to first-line treatment and require second-line therapy followed by autologous stem cell transplant. There is no one standard it possible that not all such an aggressive approach achieve cure. Quantitative analysis baseline 18F-FDG-PET-CT scans could provide a comprehensible risk-assessment complementary clinical risk-factors. Methods: We analysed from r/r cHL treated within three trials ICE, ICE brentuximab vedotin (BV) DHAP BV. For the risk model we used following parameters: vs relapse, age, Ann Arbor stage B-symptoms. Metabolic tumor volume (MTV) was calculated using fixed threshold uptake value (SUV) ≥4.0. Radiomics features were extracted in compliance Image Biomarker Standardization Initiative. developed predictive for 3-year time progression (TTP) logistic regression backward selection on robust radiomics features, e.g. SUVpeak (highest 1mL region FDG uptake) several novel dispersity representing dissemination differences SUV lesions patient. Results cross-validated (CV) validated independent external cohort. High-risk groups defined based prevalence events training cohort (22/110; 20%). Results: included 174 patients; n = 110 set (BV-DHAP BV-ICE cohort) 64 validation (ICE cohort). The resulted area under curve (AUC) 0.81 (tAUC), CV-AUC 0.76 AUC 0.74 (vAUC). 6 PET features: MTV 5 features. showed tAUC 0.73, 0.63 vAUC 0.70. Combining parameters yielded 0.90, 0.79 0.77. Using combined set, high-risk group (n 22) had TTP 38% 90% low-risk 88; p < 0.0001; Fig1A). In 39% 80% high- 13) 51; 0.0011; Fig1B). Fig1C example PET-CT two IV disease high low prediction score. EA - previously submitted EHA 2021. research funded by: SHOW foundation (Amsterdam UMC donation fund support hematology/oncology scientific research) Keywords: Diagnostic Prognostic Biomarkers, PET-CT, No conflicts interests pertinent abstract.
منابع مشابه
The management of patients with limited-stage classical Hodgkin lymphoma.
The term limited-stage Hodgkin lymphoma refers to those patients with stage I-II disease and an absence of bulky disease. Among those patients with classical Hodgkin lymphoma, approximately one-third of patients will fall into this category. As long-term disease control can now be anticipated in more than 90% of these patients, management strategies must increasingly address the need to reduce ...
متن کاملNovel treatment strategies for patients with relapsed classical Hodgkin lymphoma.
The treatment of patients with relapsed and refractory Hodgkin lymphoma (HL), especially those who relapse after autologous stem cell transplantation, remains challenging. Patients with HL whose disease relapses after stem cell transplantation are rarely cured with current treatment modalities, and have a median survival of less than 3 years. Since no new drugs have been approved by the FDA for...
متن کاملHodgkin Lymphoma and Anaplastic Variants of Non-Hodgkin Lymphoma
Background and Objectives: Classic Hodgkin lymphoma (CHL), anaplastic large cell lymphoma (ALCL) and some cases of diffuse large B cell lymphoma (DLBCL) have overlapping morphologic features. Since they all represent distinct clinico-pathologic entities, we explored the differential diagnostic impact of immunophenotyping to discriminate between them. Materials and Methods:...
متن کاملTargeted therapy in relapsed classical hodgkin lymphoma.
Although frontline treatment of advanced Hodgkin lymphoma (HL) produces high cure rates, disease either will not respond to or will relapse after initial therapy in approximately a quarter of patients. Many patients with disease relapse can be successfully salvaged with second-line chemotherapy followed by autologous stem cell transplantation (ASCT). Patients whose disease relapses after ASCT a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematological Oncology
سال: 2021
ISSN: ['1099-1069', '0278-0232']
DOI: https://doi.org/10.1002/hon.21_2879